MediciNova Drug Tipelukast Shows HDL Gains in Liver Trial
MN-001 raised HDL cholesterol and cut triglycerides in a clinical trial, with early signs of reduced liver fat and body weight.
MediciNova has released topline results from its MN-001-NATG-202 clinical trial of MN-001, the compound also known as tipelukast, showing a range of statistically significant metabolic improvements in enrolled patients.
The trial found statistically significant increases in both HDL cholesterol — commonly referred to as "good" cholesterol — and HDL particle count, or HDL-P. Elevated HDL levels are broadly associated with reduced cardiovascular risk, making the findings potentially relevant beyond the trial's primary indication.
Read more The9's Mobile Game Tops Hong Kong App Store and Google Play Charts →
Investigators also reported a significant early reduction in triglycerides, a type of blood fat linked to metabolic disease, alongside a measurable decrease in body weight among participants. The compound additionally produced a numerical improvement in liver fat, a marker relevant to conditions such as non-alcoholic fatty liver disease, though that result fell short of statistical significance thresholds described in the release.
The combination of lipid, weight, and hepatic signals could position tipelukast as a candidate for broader metabolic indications, though MediciNova has not announced plans for a follow-on study based on these results. Clinical trial data of this nature typically requires regulatory review and additional study phases before any therapeutic claims can be advanced.
Continue reading at GlobeNewswire - Industry News on Financial Services.
